t Association in its latest guidelines are
intended to help more people survive a cardiac arrest and with their brain
function intact. Studies like the NIH funded study are believed to be among
the best methods to prove how treatments can impact outcomes.
Advanced Circulatory Systems' mission is to restore life and improve
the quality of life for patients suffering cardiac arrest, low blood
pressure and head injury by developing new technologies to non-invasively
increase circulation throughout the body, providing improved opportunity
for survival and quality of life. The privately held company is based in
Minneapolis, MN.
Media contact: Joanne Henry, 612-843-2142, jhenry@henryschafer.com
Advanced Circulatory Systems medical contact: Keith Lurie, M.D., Chief
Medical Officer, 952-947-9590, klurie@advancedcirculatory.com
The generally cleared indication for the ResQPOD is a temporary
increase in blood circulation during emergency care, hospital, clinic and
home use. Studies are ongoing in the United States to evaluate the
long-term benefit of the ResQPOD for indications related to patients
suffering from cardiac arrest, hypotension during dialysis and severe blood
loss. The references in this communication are not intended to imply
specific outcome-based claims not yet cleared by the US Food and Drug
Administration. Clinical study references are available upon request.
'/>"/>SOURCE Advanced Circulatory Systems, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 Related medicine news :1.
Survival differences by race most apparent in advanced stages of breast cancer2.
Patients with Medicaid and those lacking insurance have higher risk of advanced laryngeal cancer3.
Advanced Age No Bar to Liver Transplant4.
Oncologists are critical in managing psychiatric disorders in patients with advanced cancer5.
Advanced technologies aim to transform the coaching of top athletes6.
Mecklenburg EMS Introduces Most-Advanced Situational Training in America for Emergency Medical Personnel7.
Advanced Life Sciences Joins NASDAQ Capital Market8.
Experimental drug shows promise in advanced kidney cancer9.
TCS Healthcare Technologies Announces Full Integration of Case Management Adherence Guidelines into Acuity Advanced Care(TM) System10.
OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research11.
U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors